| Today's Top Story |  |  | | - FTC can challenge "pay-for-delay" arrangements, top court says
The Supreme Court ruled on Monday that the Federal Trade Commission can legally challenge "pay-for-delay" deals between brand-name drugmakers and makers of generics on a case-by-case basis. "Courts reviewing such agreements should proceed by applying the 'rule of reason,' rather than under a 'quick look' approach," the top court said. The ruling "will open the door to broader FTC scrutiny of brand/generic settlements," but most of these deals will likely still be allowed "even if reviewed by the FTC," an analyst said. Reuters (6/17), France 24/Agence France-Presse (6/17), CNBC (6/17), USA Today (6/17)       | Health Care & Policy | | | | - MedImmune, NGM ally to develop drugs for obesity, diabetes
AstraZeneca's MedImmune unit and NGM Biopharmaceuticals will collaborate in the discovery and development of the latter's enteroendocrine cell program for the treatment of obesity and type 2 diabetes. The firms intend to develop first-in-class peptide and antibody treatments based on the EEC hormones. The deal entitles NGM to upfront payment, research funding, milestone fees and royalties. PharmaTimes (U.K.) (6/17) - Trials of sickle cell anemia treatments underway
Recruitment has begun for a midstage clinical trial to find out whether heart disease drug Lexiscan can alleviate attacks of sickle cell anemia. The NIH-supported study will test whether the drug can relieve pain and inflammation. Meanwhile, HemaQuest has completed the recruitment of patients with sickle cell disease for a Phase IIb study involving HQK-1001, which promotes the production of fetal hemoglobin. San Diego Union-Tribune (6/16) - Athera heart drug gets $8M grant from EU
Athera Biotechnologies, Leiden University Medical Center, Turku PET Center, Clinical Trial Consultants and Smerud Medical Research received an $8 million grant from the European Union's Seventh Framework Programme for Research. The money will be used to support preclinical development of Athera's lead drug candidate PC-mAb, which is designed to help patients at high risk of atherosclerosis-related cardiovascular events. Genetic Engineering & Biotechnology News (6/17)  | Analyst Paper - ARC Brief: Infrastructure: the Hidden Optimization Opportunity
New technologies allow preventative and predictive maintenance coupled with EAM and analytics to be applied to infrastructure. Those responsible for maintaining facilities, fleets, and linear assets should investigate strategies for improving the effectiveness of the maintenance function. Learn more in the free report. |
 | Global Developments | | | |  | Customer Excellence: MedTech Business Model Innovation
L.E.K. Consulting believes there is huge opportunity for medical device and medical technology partners to innovate and move away from solely focusing on product innovation and product sales. To be successful, they must evolve towards a new "Customer Excellence" model. Download the free whitepaper. |
 | Industrial & Environmental | | | | - Algenol won't build commercial-scale biorefinery in Fla. anymore
Algenol is canceling plans to build a commercial-scale algae-to-fuel facility in Florida after Gov. Rick Scott signed a bill repealing the state's 10% ethanol standard. "I can't make a decision in this state that doesn't support what we're doing," CEO Paul Woods said. Algenol is considering moving forward in Texas, New Mexico, Arizona or another state. WBBH-TV (Fort Myers, Fla.) (6/12) | News from BIO | | | | - Save on energy costs through BIO's newest cost-savings program
BIO has recently aligned with APPI Energy, an energy consulting firm, to assist member companies with reducing their energy expenses. APPI Energy, the preferred energy consultant of 140 trade associations and chambers of commerce nationwide, provides solutions to reduce electricity and natural gas costs at no risk or obligation to member companies. Through this program, APPI Energy offers specialized energy cost reduction services, including the identification of reliable and competitive energy suppliers for member companies and the obtaining of competitive bids from the preferred suppliers in deregulated energy markets. Learn more.
| SmartQuote | | | |  | A human being can survive almost anything, as long as she sees the end in sight."
--Elizabeth Wurtzel,
American writer and journalist  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, June 17, 2013
- Friday, June 14, 2013
- Thursday, June 13, 2013
- Wednesday, June 12, 2013
- Tuesday, June 11, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment